Hyderabad-based pharmaceutical company Gland Pharma announced that it will announce four new complex injectables during the current financial year. The generic-injectable-focused company reported a 38 per cent rise in profit after tax on annual basis at ₹302.1 crore for the second quarter of financial year 2021-22, as opposed to ₹218.9 crore in the year-ago period.
“We continue to focus on revenue diversification across geographies, which is helping us further improve our manufacturing efficiencies because of benefits from scale as well as de-risking the business. With declining Covid-19 hospitalisations, we observed a shift in product mix,” said Srinivas Sadu, MD and CEO of Gland Pharma.
“Our wide therapeutic portfolio helped us to sustain growth despite changing market demand. Our rich R&D pipeline is helping us maintain strong momentum of new product launches. We are on track to make four complex injectable filings in this financial year,” he further added.
Subscribe to Mint Newsletters * Enter a valid email * Thank you for subscribing to our newsletter.
Never miss a story! Stay connected and informed with Mint.
our App Now!!